TVRDTvardi Therapeutics, Inc.

TVRD Stock Price, Valuation & Chart | Tvardi Therapeutics, Inc.

Compare

$1.880+0.14 (+7.74%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology TVRD intrinsic value TVRD calculated fair value vs price

Overview Financials Dividends Ratios

TVRD Historical price chart

TVRD Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization17.64M

PE Ratio-0.67

EPS-2.79

Trading Volume106.72K

Today's High/Low1.88/1.75

Dividend Yield0.00

52 Week High/Low43.65/1.5

Shares Outstanding9.38M

TVRD Financial Statement

TVRD Analyst ratings

TVRD Analysis & performance metrics

TVRD Company profile

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases…

Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).

TVRD Management team

Name

Position

David J. Tweardy M.D.

Co-Founder & Scientific Advisory Board Member

John Kauh M.D.

Chief Medical Officer

Ronald A. DePinho M.D.

Co-Founder & Chairman of Scientific Advisory Board

Jeffrey Larson DABT, Ph.D.

Senior Vice President of R&D

Yixin Chen Ph.D.

Vice President of CMC

Imran Alibhai Ph.D.CEO

Chief Executive Officer & Director

Michael T. Lewis Ph.D.

Co-Founder & Scientific Advisory Board Member

Dan Conn J.D., M.B.A.CFO

Chief Financial Officer

Name

Position

David J. Tweardy M.D.

Co-Founder & Scientific Advisory Board Member

John Kauh M.D.

Chief Medical Officer

Ronald A. DePinho M.D.

Co-Founder & Chairman of Scientific Advisory Board

Jeffrey Larson DABT, Ph.D.

Senior Vice President of R&D

Yixin Chen Ph.D.

Vice President of CMC

Imran Alibhai Ph.D.CEO

Chief Executive Officer & Director

Michael T. Lewis Ph.D.

Co-Founder & Scientific Advisory Board Member

Dan Conn J.D., M.B.A.CFO

Chief Financial Officer

Management Team

David J. Tweardy M.D.

Co-Founder & Scientific Advisory Board Member

John Kauh M.D.

Chief Medical Officer

Ronald A. DePinho M.D.

Co-Founder & Chairman of Scientific Advisory Board

Jeffrey Larson DABT, Ph.D.

Senior Vice President of R&D

Yixin Chen Ph.D.

Vice President of CMC

Imran Alibhai Ph.D.CEO

Chief Executive Officer & Director

Michael T. Lewis Ph.D.

Co-Founder & Scientific Advisory Board Member

Dan Conn J.D., M.B.A.CFO

Chief Financial Officer

Management

David J. Tweardy M.D.

Co-Founder & Scientific Advisory Board Member

John Kauh M.D.

Chief Medical Officer

Ronald A. DePinho M.D.

Co-Founder & Chairman of Scientific Advisory Board

Jeffrey Larson DABT, Ph.D.

Senior Vice President of R&D

Yixin Chen Ph.D.

Vice President of CMC

Imran Alibhai Ph.D.CEO

Chief Executive Officer & Director

Michael T. Lewis Ph.D.

Co-Founder & Scientific Advisory Board Member

Dan Conn J.D., M.B.A.CFO

Chief Financial Officer

Total 8 executives

TVRD Frequently asked questions

What is Tvardi Therapeutics, Inc. (TVRD) Stock Price?

Current stock price of Tvardi Therapeutics, Inc. (TVRD) stock is $1.880. The stock price is +7.74% higher in the session. The intraday range can be seen from this page. Volume of Tvardi Therapeutics, Inc. (TVRD) stock is 106.72K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Tvardi Therapeutics, Inc. (TVRD) stock price going up or down today?

The stock price of Tvardi Therapeutics, Inc. (TVRD) can change with earnings, company news, and overall market sentiment. Tvardi Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Tvardi Therapeutics, Inc. stock expensive at its current price?

Whether Tvardi Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for TVRD on this page is -0.67. EPS on this page is -2.79. Compare those figures with peers and growth expectations before deciding if the current Tvardi Therapeutics, Inc. price is justified.

How has the stock price of Tvardi Therapeutics, Inc. (TVRD) performed historically?

Historical performance for Tvardi Therapeutics, Inc. (TVRD) is shown on the price chart on this page. Review multi-period moves alongside volume to see how TVRD reacted to past earnings and market events.

Should I buy Tvardi Therapeutics, Inc. (TVRD) stock, at this price?

Buying Tvardi Therapeutics, Inc. (TVRD) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.